The effectiveness of trivalent inactivated influenza vaccine in children over six consecutive influenza seasons
Abstract Objective To estimate the effectiveness of two doses of trivalent inactivated influenza vaccine (TIV) over six consecutive influenza seasons in a small community in Japan. Patients and methods A prospective, non-randomized, observational study of TIV effectiveness was performed involving ch...
Gespeichert in:
Veröffentlicht in: | Vaccine 2011-02, Vol.29 (9), p.1844-1849 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1849 |
---|---|
container_issue | 9 |
container_start_page | 1844 |
container_title | Vaccine |
container_volume | 29 |
creator | Katayose, Masahiko Hosoya, Mitsuaki Haneda, Takashi Yamaguchi, Hideo Kawasaki, Yukihiko Sato, Masatoki Wright, Peter F |
description | Abstract Objective To estimate the effectiveness of two doses of trivalent inactivated influenza vaccine (TIV) over six consecutive influenza seasons in a small community in Japan. Patients and methods A prospective, non-randomized, observational study of TIV effectiveness was performed involving children aged 6 months to 6 years accessing pediatric services in Soma and Shinchi, Japan. The total number of children under observation was 14,788. Each fall from 2002 to 2007 TIV was offered to all children with an average uptake of 52.9%. Influenza rapid diagnostic tests were performed to all children with respiratory symptoms and a temperature >38 °C during each surveillance period. The efficacy of two doses of TIV was estimated by the relative risk of influenza illness and influenza associated hospitalizations and effectiveness by reduction in all respiratory illness in vaccinated and unvaccinated children. Results Influenza A occurred each year resulting in approximately one in five children in the unvaccinated group having an influenza A related clinic visit. For influenza A, two doses of TIV showed yearly efficacies that ranged from 42% to 69% with the highest efficacy during the 2002/2003 influenza season when the vaccine strains were well matched with the circulating viruses. The overall efficacy of two doses of TIV against influenza A and B associated illness was 52% and 59%, respectively. TIV also reduced the rate of the influenza associated hospitalizations attributable to both influenza A and B. Conclusions Vaccination with two doses of TIV was consistently effective in preventing influenza-associated clinic visits and hospitalizations. |
doi_str_mv | 10.1016/j.vaccine.2010.12.049 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_864961636</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X10018220</els_id><sourcerecordid>864961636</sourcerecordid><originalsourceid>FETCH-LOGICAL-c575t-fe878cb61452a3cea5f1fd0806d836706b66994fe59df1d4c0893544c719eeba3</originalsourceid><addsrcrecordid>eNqFkk1v1DAQhiMEokvhJ4AiIcQpy4xjO86FClV8SZU4UCRultcZq16yTrGTiPLrcbSBol56suV53hnPvFMUzxG2CCjf7LezsdYH2jJY3tgWePug2KBq6ooJVA-LDTDJK47w_aR4ktIeAESN7ePihCG2QgHbFMPlFZXkHNnRzxQopXJw5Rj9bHoKY-mDWSJmpC7fXT9R-G3KtXR-Ke2V77tIoRxmimXyv0o7hER2WvL9J0lkUg48LR450yd6tp6nxbcP7y_PP1UXXz5-Pn93UVnRiLFypBpldxK5YKa2ZIRD14EC2alaNiB3UrYtdyTazmHHLai2FpzbBluinalPi9fHvNdx-DlRGvXBJ0t9bwINU9JK8lairOX9pAAhoWY8ky_vkPthiiG3oZG3ChEkikyJI2XjkFIkp6-jP5h4oxH0Yp3e63V-erFOI9PZuqx7sWafdgfq_qn-epWBVytgkjW9iyZYn265WjXI5MKdHTnK8509RZ2sp2Cp8zHbrLvB3_uVt3cy2N4Hn4v-oBtKt13rlAX667Jny5ohACrGoP4Dao_PtQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1498110615</pqid></control><display><type>article</type><title>The effectiveness of trivalent inactivated influenza vaccine in children over six consecutive influenza seasons</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Katayose, Masahiko ; Hosoya, Mitsuaki ; Haneda, Takashi ; Yamaguchi, Hideo ; Kawasaki, Yukihiko ; Sato, Masatoki ; Wright, Peter F</creator><creatorcontrib>Katayose, Masahiko ; Hosoya, Mitsuaki ; Haneda, Takashi ; Yamaguchi, Hideo ; Kawasaki, Yukihiko ; Sato, Masatoki ; Wright, Peter F</creatorcontrib><description>Abstract Objective To estimate the effectiveness of two doses of trivalent inactivated influenza vaccine (TIV) over six consecutive influenza seasons in a small community in Japan. Patients and methods A prospective, non-randomized, observational study of TIV effectiveness was performed involving children aged 6 months to 6 years accessing pediatric services in Soma and Shinchi, Japan. The total number of children under observation was 14,788. Each fall from 2002 to 2007 TIV was offered to all children with an average uptake of 52.9%. Influenza rapid diagnostic tests were performed to all children with respiratory symptoms and a temperature >38 °C during each surveillance period. The efficacy of two doses of TIV was estimated by the relative risk of influenza illness and influenza associated hospitalizations and effectiveness by reduction in all respiratory illness in vaccinated and unvaccinated children. Results Influenza A occurred each year resulting in approximately one in five children in the unvaccinated group having an influenza A related clinic visit. For influenza A, two doses of TIV showed yearly efficacies that ranged from 42% to 69% with the highest efficacy during the 2002/2003 influenza season when the vaccine strains were well matched with the circulating viruses. The overall efficacy of two doses of TIV against influenza A and B associated illness was 52% and 59%, respectively. TIV also reduced the rate of the influenza associated hospitalizations attributable to both influenza A and B. Conclusions Vaccination with two doses of TIV was consistently effective in preventing influenza-associated clinic visits and hospitalizations.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2010.12.049</identifier><identifier>PMID: 21195802</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Age ; Age Factors ; Allergy and Immunology ; Applied microbiology ; Biological and medical sciences ; Child, Preschool ; Children ; Confidence intervals ; Fundamental and applied biological sciences. Psychology ; Hospitalization ; Hospitals ; Humans ; Illnesses ; Immunization ; Infant ; Influenza ; Influenza Vaccines - immunology ; Influenza Vaccines - therapeutic use ; Influenza, Human - epidemiology ; Influenza, Human - immunology ; Influenza, Human - prevention & control ; Japan - epidemiology ; Microbiology ; Mortality ; Observational studies ; Pediatrics ; Pharmaceuticals ; Prospective Studies ; Public health ; Seasons ; Vaccine ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Vaccines, Inactivated - immunology ; Vaccines, Inactivated - therapeutic use</subject><ispartof>Vaccine, 2011-02, Vol.29 (9), p.1844-1849</ispartof><rights>Elsevier Ltd</rights><rights>2011 Elsevier Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Feb 17, 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c575t-fe878cb61452a3cea5f1fd0806d836706b66994fe59df1d4c0893544c719eeba3</citedby><cites>FETCH-LOGICAL-c575t-fe878cb61452a3cea5f1fd0806d836706b66994fe59df1d4c0893544c719eeba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1498110615?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23871262$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21195802$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Katayose, Masahiko</creatorcontrib><creatorcontrib>Hosoya, Mitsuaki</creatorcontrib><creatorcontrib>Haneda, Takashi</creatorcontrib><creatorcontrib>Yamaguchi, Hideo</creatorcontrib><creatorcontrib>Kawasaki, Yukihiko</creatorcontrib><creatorcontrib>Sato, Masatoki</creatorcontrib><creatorcontrib>Wright, Peter F</creatorcontrib><title>The effectiveness of trivalent inactivated influenza vaccine in children over six consecutive influenza seasons</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Abstract Objective To estimate the effectiveness of two doses of trivalent inactivated influenza vaccine (TIV) over six consecutive influenza seasons in a small community in Japan. Patients and methods A prospective, non-randomized, observational study of TIV effectiveness was performed involving children aged 6 months to 6 years accessing pediatric services in Soma and Shinchi, Japan. The total number of children under observation was 14,788. Each fall from 2002 to 2007 TIV was offered to all children with an average uptake of 52.9%. Influenza rapid diagnostic tests were performed to all children with respiratory symptoms and a temperature >38 °C during each surveillance period. The efficacy of two doses of TIV was estimated by the relative risk of influenza illness and influenza associated hospitalizations and effectiveness by reduction in all respiratory illness in vaccinated and unvaccinated children. Results Influenza A occurred each year resulting in approximately one in five children in the unvaccinated group having an influenza A related clinic visit. For influenza A, two doses of TIV showed yearly efficacies that ranged from 42% to 69% with the highest efficacy during the 2002/2003 influenza season when the vaccine strains were well matched with the circulating viruses. The overall efficacy of two doses of TIV against influenza A and B associated illness was 52% and 59%, respectively. TIV also reduced the rate of the influenza associated hospitalizations attributable to both influenza A and B. Conclusions Vaccination with two doses of TIV was consistently effective in preventing influenza-associated clinic visits and hospitalizations.</description><subject>Age</subject><subject>Age Factors</subject><subject>Allergy and Immunology</subject><subject>Applied microbiology</subject><subject>Biological and medical sciences</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Confidence intervals</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Hospitalization</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Illnesses</subject><subject>Immunization</subject><subject>Infant</subject><subject>Influenza</subject><subject>Influenza Vaccines - immunology</subject><subject>Influenza Vaccines - therapeutic use</subject><subject>Influenza, Human - epidemiology</subject><subject>Influenza, Human - immunology</subject><subject>Influenza, Human - prevention & control</subject><subject>Japan - epidemiology</subject><subject>Microbiology</subject><subject>Mortality</subject><subject>Observational studies</subject><subject>Pediatrics</subject><subject>Pharmaceuticals</subject><subject>Prospective Studies</subject><subject>Public health</subject><subject>Seasons</subject><subject>Vaccine</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Vaccines, Inactivated - immunology</subject><subject>Vaccines, Inactivated - therapeutic use</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkk1v1DAQhiMEokvhJ4AiIcQpy4xjO86FClV8SZU4UCRultcZq16yTrGTiPLrcbSBol56suV53hnPvFMUzxG2CCjf7LezsdYH2jJY3tgWePug2KBq6ooJVA-LDTDJK47w_aR4ktIeAESN7ePihCG2QgHbFMPlFZXkHNnRzxQopXJw5Rj9bHoKY-mDWSJmpC7fXT9R-G3KtXR-Ke2V77tIoRxmimXyv0o7hER2WvL9J0lkUg48LR450yd6tp6nxbcP7y_PP1UXXz5-Pn93UVnRiLFypBpldxK5YKa2ZIRD14EC2alaNiB3UrYtdyTazmHHLai2FpzbBluinalPi9fHvNdx-DlRGvXBJ0t9bwINU9JK8lairOX9pAAhoWY8ky_vkPthiiG3oZG3ChEkikyJI2XjkFIkp6-jP5h4oxH0Yp3e63V-erFOI9PZuqx7sWafdgfq_qn-epWBVytgkjW9iyZYn265WjXI5MKdHTnK8509RZ2sp2Cp8zHbrLvB3_uVt3cy2N4Hn4v-oBtKt13rlAX667Jny5ohACrGoP4Dao_PtQ</recordid><startdate>20110217</startdate><enddate>20110217</enddate><creator>Katayose, Masahiko</creator><creator>Hosoya, Mitsuaki</creator><creator>Haneda, Takashi</creator><creator>Yamaguchi, Hideo</creator><creator>Kawasaki, Yukihiko</creator><creator>Sato, Masatoki</creator><creator>Wright, Peter F</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20110217</creationdate><title>The effectiveness of trivalent inactivated influenza vaccine in children over six consecutive influenza seasons</title><author>Katayose, Masahiko ; Hosoya, Mitsuaki ; Haneda, Takashi ; Yamaguchi, Hideo ; Kawasaki, Yukihiko ; Sato, Masatoki ; Wright, Peter F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c575t-fe878cb61452a3cea5f1fd0806d836706b66994fe59df1d4c0893544c719eeba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Age</topic><topic>Age Factors</topic><topic>Allergy and Immunology</topic><topic>Applied microbiology</topic><topic>Biological and medical sciences</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Confidence intervals</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Hospitalization</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Illnesses</topic><topic>Immunization</topic><topic>Infant</topic><topic>Influenza</topic><topic>Influenza Vaccines - immunology</topic><topic>Influenza Vaccines - therapeutic use</topic><topic>Influenza, Human - epidemiology</topic><topic>Influenza, Human - immunology</topic><topic>Influenza, Human - prevention & control</topic><topic>Japan - epidemiology</topic><topic>Microbiology</topic><topic>Mortality</topic><topic>Observational studies</topic><topic>Pediatrics</topic><topic>Pharmaceuticals</topic><topic>Prospective Studies</topic><topic>Public health</topic><topic>Seasons</topic><topic>Vaccine</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Vaccines, Inactivated - immunology</topic><topic>Vaccines, Inactivated - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Katayose, Masahiko</creatorcontrib><creatorcontrib>Hosoya, Mitsuaki</creatorcontrib><creatorcontrib>Haneda, Takashi</creatorcontrib><creatorcontrib>Yamaguchi, Hideo</creatorcontrib><creatorcontrib>Kawasaki, Yukihiko</creatorcontrib><creatorcontrib>Sato, Masatoki</creatorcontrib><creatorcontrib>Wright, Peter F</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Katayose, Masahiko</au><au>Hosoya, Mitsuaki</au><au>Haneda, Takashi</au><au>Yamaguchi, Hideo</au><au>Kawasaki, Yukihiko</au><au>Sato, Masatoki</au><au>Wright, Peter F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effectiveness of trivalent inactivated influenza vaccine in children over six consecutive influenza seasons</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2011-02-17</date><risdate>2011</risdate><volume>29</volume><issue>9</issue><spage>1844</spage><epage>1849</epage><pages>1844-1849</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Abstract Objective To estimate the effectiveness of two doses of trivalent inactivated influenza vaccine (TIV) over six consecutive influenza seasons in a small community in Japan. Patients and methods A prospective, non-randomized, observational study of TIV effectiveness was performed involving children aged 6 months to 6 years accessing pediatric services in Soma and Shinchi, Japan. The total number of children under observation was 14,788. Each fall from 2002 to 2007 TIV was offered to all children with an average uptake of 52.9%. Influenza rapid diagnostic tests were performed to all children with respiratory symptoms and a temperature >38 °C during each surveillance period. The efficacy of two doses of TIV was estimated by the relative risk of influenza illness and influenza associated hospitalizations and effectiveness by reduction in all respiratory illness in vaccinated and unvaccinated children. Results Influenza A occurred each year resulting in approximately one in five children in the unvaccinated group having an influenza A related clinic visit. For influenza A, two doses of TIV showed yearly efficacies that ranged from 42% to 69% with the highest efficacy during the 2002/2003 influenza season when the vaccine strains were well matched with the circulating viruses. The overall efficacy of two doses of TIV against influenza A and B associated illness was 52% and 59%, respectively. TIV also reduced the rate of the influenza associated hospitalizations attributable to both influenza A and B. Conclusions Vaccination with two doses of TIV was consistently effective in preventing influenza-associated clinic visits and hospitalizations.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>21195802</pmid><doi>10.1016/j.vaccine.2010.12.049</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0264-410X |
ispartof | Vaccine, 2011-02, Vol.29 (9), p.1844-1849 |
issn | 0264-410X 1873-2518 |
language | eng |
recordid | cdi_proquest_miscellaneous_864961636 |
source | MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
subjects | Age Age Factors Allergy and Immunology Applied microbiology Biological and medical sciences Child, Preschool Children Confidence intervals Fundamental and applied biological sciences. Psychology Hospitalization Hospitals Humans Illnesses Immunization Infant Influenza Influenza Vaccines - immunology Influenza Vaccines - therapeutic use Influenza, Human - epidemiology Influenza, Human - immunology Influenza, Human - prevention & control Japan - epidemiology Microbiology Mortality Observational studies Pediatrics Pharmaceuticals Prospective Studies Public health Seasons Vaccine Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Inactivated - immunology Vaccines, Inactivated - therapeutic use |
title | The effectiveness of trivalent inactivated influenza vaccine in children over six consecutive influenza seasons |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T12%3A50%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effectiveness%20of%20trivalent%20inactivated%20influenza%20vaccine%20in%20children%20over%20six%20consecutive%20influenza%20seasons&rft.jtitle=Vaccine&rft.au=Katayose,%20Masahiko&rft.date=2011-02-17&rft.volume=29&rft.issue=9&rft.spage=1844&rft.epage=1849&rft.pages=1844-1849&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2010.12.049&rft_dat=%3Cproquest_cross%3E864961636%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1498110615&rft_id=info:pmid/21195802&rft_els_id=S0264410X10018220&rfr_iscdi=true |